⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CYTK News
Cytokinetics Inc.
Form 8-K
sec.gov
CYTK
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
CYTK
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
globenewswire.com
CYTK
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
globenewswire.com
CYTK
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
globenewswire.com
CYTK
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
accessnewswire.com
CYTK
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation
accessnewswire.com
CYTK
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect
accessnewswire.com
CYTK
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out
accessnewswire.com
CYTK
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation
accessnewswire.com
CYTK